Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Antipyrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 5/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | MC3R | P41968 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.45 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caffeine SCHEMBL452067 | 0.83 | ADORA2B (0.64) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Caffeine SCHEMBL28250257 | 0.81 | ADORA2B (0.61) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Caffeine SCHEMBL6013759 | 0.80 | ADORA2B (0.59) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Caffeine SCHEMBL28537613 | 0.77 | ADORA2B (0.54) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Caffeine SCHEMBL6013758 | 0.77 | TNF (0.57) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Caffeine SCHEMBL20797203 | 0.75 | ADORA2B (0.52) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Caffeine SCHEMBL20797205 | 0.75 | ADORA2B (0.52) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Caffeine SCHEMBL2409052 | 0.74 | ADORA2B (0.51) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Caffeine SCHEMBL29657639 | 0.71 | ADORA2B (0.52) | ADORA2BPIK3CDPOLBADORA3CNR1 | |
| Ampyrone SCHEMBL27612823 | 0.70 | BCHE (0.61) | ADORA2BPIK3CDPOLBADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | claimed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | claimed |
| EP-2042162-B1 | PROCESS FOR PRODUCING SPHERICAL ELEMENTARY GRANULE CONTAINING READILY WATER-SOLUBLE DRUG | ASAHI CHEMICAL IND (JP) | 2017-10-04 | — | — | EP | claimed |
| EP-2050439-B1 | PROCESS FOR PRODUCTION OF SPHERICAL GRANULE CONTAINING SLIGHTLY WATER-SOLUBLE SUBSTANCE | ASAHI CHEMICAL IND (JP) | 2016-11-23 | — | — | EP | claimed |
| US-RE45810-E1 | Process for producing spherical base granule comprising easily water-soluble drug | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-11-24 | — | — | US | claimed |
| US-9095512-B2 | Method for producing spherical base granules comprising hardly water-soluble drug | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-08-04 | — | — | US | claimed |
| US-8568785-B2 | Process for producing spherical base granule comprising easily water-soluble drug | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2013-10-29 | — | — | US | claimed |
| US-20090280186-A1 | PROCESS FOR PRODUCING SPHERICAL BASE GRANULE COMPRISING EASILY WATER-SOLUBLE DRUG | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-11-12 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| WO-2025097123-A1 | COMPOSITIONS AND METHODS TO TREAT ALZHEIMER'S DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2025-05-08 | — | — | WO | disclosed |
| US-4789667-A | ANTIINFLAMMATORY AGENT AND PYROGLUTAMATES AS PENETRATION ENHANCERS | TEIJIN LIMITED (JP) | 1988-12-06 | — | — | US | disclosed |
| US-4746675-A | ENHANCED PENETRATION OF DRUG THROUGH SKIN OR MUCOSA | TEIJIN LIMITED (JP) | 1988-05-24 | — | — | US | disclosed |
| EP-0123948-B1 | EXTERNAL PHARMACEUTICAL COMPOSITION | TEIJIN LIMITED (JP) | 1987-09-30 | — | — | EP | disclosed |
| EP-0173990-A2 | External pharmaceutical composition | TEIJIN LIMITED (JP) | 1986-03-12 | — | — | EP | disclosed |
| EP-0123948-A1 | External pharmaceutical composition | TEIJIN LIMITED (JP) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | ADORA2B 2113/4885PIK3CD 598/4885POLB 4240/4885 |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | CBR3, SLC13A3, CYP3A5 | ADORA2B 1183/4885PIK3CD 3570/4885POLB 4621/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | ADORA2B 3323/4885PIK3CD 3132/4885POLB 3575/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | ADORA2B 3323/4885PIK3CD 3132/4885POLB 3575/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | ADORA2B 3734/4885PIK3CD 4482/4885POLB 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.